Novel mechanisms in the regulation of phosphorus homeostasis

Physiology

Volumn 24, Issue 1, 2009, Pages 17-25

  Berndt, Theresa ^a   Kumar, Rajiv ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ANIMAL; HOMEOSTASIS; HUMAN; INTESTINE; KIDNEY; METABOLISM; PHOSPHATE INTAKE; PHYSIOLOGY; REVIEW; TIME;

ANIMALS; HOMEOSTASIS; HUMANS; INTESTINES; KIDNEY; PARATHYROID HORMONE; PHOSPHORUS; PHOSPHORUS, DIETARY; TIME FACTORS; VITAMIN D;

EID: 59849097605     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00034.2008     Document Type: Review

References (82)

1. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in F.GF23. Nat Genet 26: 345-348, 2000.
2. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 5269-5279, 2004.
3. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112: 785-794, 2003.
4. Berndt T, Knox FG. Renal Regulation of Phosphate Excretion. New York: Raven Press, 1992.
5. Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 69: 341-359, 2007.
6. Berndt T, Thomas LF, Craig TA, Sommer S, Li X, Bergstralh EJ, Kumar R. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc Natl Acad Sci USA 104: 11085-11090, 2007.
7. Berndt TJ, Bielesz B, Craig TA, Tebben PJ, Bacic D, Wagner CA, O'Brien S, Schiavi S, Biber J, Murer H, Kumar R. Secreted frizzled-related protein-4 reduces sodium-phosphate co-transporter abundance and activity in proximal tubule cells. Pflügers Arch 451: 579-587, 2006.
8. Berndt TJ, Craig TA, McCormick DJ, Lanske B, Sitara D, Razzaque MS, Pragnell M, Bowe AE, O'Brien SP, Schiavi SC, Kumar R. Biological activity of FGF-23 fragments. Pflügers Arch 454: 615-623, 2007.
9. Berndt TJ, Schiavi S, Kumar R. "Phosphatonins" and the regulation of phosphorus homeostasis. Am J Physiol Renal Physiol 289: F1170-F1182, 2005.
10. Bessman SP, Carpenter CL. The creatine-creatine phosphate energy shuttle. Annu Rev Biochem 54: 831-862, 1985.
11. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284: 977-981, 2001.
12. Brown EM. Clinical lessons from the calcium-sensing receptor. Nat Clin Pract Endocrinol Metab 3: 122-133, 2007.
13. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of Cterminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196, 2006.
14. Cai Q, Hodgson SF, Kao PC, Lennon VA, Klee GG, Zinsmiester AR, Kumar R. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med 330: 1645-1649, 1994.
15. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90: 1012-1020, 2005.
16. 2+-sensing receptor in rat intestine. Am J Physiol Gastrointest Liver Physiol 274: G122-G130, 1998.
17. Chen TC, Castillo L, Korycka-Dahl M, DeLuca HF. Role of vitamin D metabolites in phosphate transport of rat intestine. J Nutr 104: 1056-1060, 1974.
18. Condamine L, Menaa C, Vrtovsnik F, Friedlander G, Garabedian M. Local action of phosphate depletion and insulin-like growth factor 1 on in vitro production of 1,25-dihydroxyvitamin D by cultured mammalian kidney cells. J Clin Invest 94: 1673-1679, 1994.
19. De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S, Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA, Schiavi SC. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17: 1102-1110, 2002.
20. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80: 1689S-1696S, 2004.
21. DeLuca HF. Vitamin D: revisited 1980. Clin Endocrinol Metab 9: 1-26, 1980.
22. Diem K, Lentner C. Giegy Scientific Tables. New York: Geigy Pharmacueticals, 1970.
23. Econs MJ, Drezner MK. Tumor-induced osteomalacia: unveiling a new hormone. N Engl J Med 330: 1679-1681, 1994.
24. Ferrari SL, Bonjour JP, Rizzoli R. FGF-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2004.
25. Fruman DA, Meyers RE, Cantley LC. Phosphoinositide kinases. Annu Rev Biochem 67: 481-507, 1998.
26. Fujita T, Izumo N, Fukuyama R, Meguro T, Nakamuta H, Kohno T, Koida M. Phosphate provides an extracellular signal that drives nuclear export of Runx2/Cbfa1 in bone cells. Biochem Biophys Res Commun 280: 348-352, 2001.
27. Goseki-Sone M, Yamada A, Asahi K, Hirota A, Ezawa I, Iimura T. Phosphate depletion enhances tissue-nonspecific alkaline phosphatase gene expression in a cultured mouse marrow stromal cell line ST2. Biochem Biophys Res Commun 265: 24-28, 1999.
28. Goseki-Sone M, Yamada A, Hamatani R, Mizoi L, Iimura T, Ezawa I. Phosphate depletion enhances bone morphogenetic protein-4 gene expression in a cultured mouse marrow stromal cell line ST2. Biochem Biophys Res Commun 299: 395-399, 2002.
29. Gowen LC, Petersen DN, Mansolf AL, Qi H, Stock JL, Tkalcevic GT, Simmons HA, Crawford DT, Chidsey-Frink KL, Ke HZ, McNeish JD, Brown TA. Targeted disruption of the osteoblast/osteocyte factor 45 gene (OF45) results in increased bone formation and bone mass. J Biol Chem 278: 1998-2007, 2003.
30. Hansen NM, Felix R, Bisaz S, Fleisch H. Aggregation of hydroxyapatite crystals. Biochim Biophys Acta 451: 549-559, 1976.
31. Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Min Metab 25: 419-422, 2007.
32. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW. Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89: 4158-4161, 2004.
33. Jencks WP. From chemistry to biochemistry to catalysis to movement. Annu Rev Biochem 66: 1-18, 1997.
34. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 137: 203-220, 1977.
35. Knochel JP, Barcenas C, Cotton JR, Fuller TJ, Haller R, Carter NW. Hypophosphatemia and rhabdomyolysis. Trans Assoc Am Physicians 91: 156-168, 1978.
36. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005.
37. Kornberg A. The enzymatic replication of DNA. CRC Crit Rev Biochem 7: 23-43, 1979.
38. Krebs EG, Beavo JA. Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem 48: 923-959, 1979.
39. Kumar R. The phosphatonins and the regulation of phosphate homeostasis. Annales d'Endocrinologie 67: 142-146, 2006.
40. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123, 2006.
41. Lamarche MG, Wanner BL, Crepin S, Harel J. The phosphate regulon and bacterial virulence: a regulatory network connecting phosphate homeostasis and pathogenesis. FEMS Microbiol Rev 32: 461-473, 2008.
42. Lardy HA, Ferguson SM. Oxidative phosphorylation in mitochondria. Annu Rev Biochem 38: 991-1034, 1969.
43. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 3087-3094, 2004.
44. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003.
45. Lee DB, Walling MW, Brautbar N. Intestinal phosphate absorption: influence of vitamin D and non-vitamin D factors. Am J Physiol Gastrointest Liver Physiol 250: G369-G373, 1986.
46. Lehninger AL, Wadkins CL. Oxidative phosphorylation. Annu Rev Biochem 31: 47-78, 1962.
47. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19: 2342-2350, 2008.
48. i deprivation involves mRNA stability. Pflügers Arch 430: 459-463, 1995.
49. Marks J, Churchill LJ, Debnam ES, Unwin RJ. Matrix extracellular phosphoglycoprotein inhibits phosphate transport. J Am Soc Nephrol 19: 2313-2320, 2008.
50. Martin DR, Ritter CS, Slatopolsky E, Brown AJ. Acute regulation of parathyroid hormone by dietary phosphate. Am J Physiol Endocrinol Metab 289: E729-E734, 2005.
51. Mouillon JM, Persson BL. New aspects on phosphate sensing and signaling in Saccharomyces cerevisiae. FEMS Yeast Res 6: 171-176, 2006.
52. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006.
53. Op den Kamp JA. Lipid asymmetry in membranes. Annu Rev Biochem 48: 47-71, 1979.
54. Perwad F, Azam M, Zhang M, Yamashita T, Tennenhouse H, Portale A. Dietary phosphorus regulates serum FGF-23 concentrations and 1, 25(OH)2D3 metabolism in mice. J Bone Miner Res 19: S251, 2004.
55. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 5358-5364, 2005.
56. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 293: F1577-F1583, 2007.
57. Rizzoli R, Fleisch H, Bonjour JP. Role of 1,25-dihydroxyvitamin D3 on intestinal phosphate absorption in rats with a normal vitamin D supply. J Clin Invest 60: 639-647, 1977.
58. Rothfield L, Finkelstein A. Membrane biochemistry. Annu Rev Biochem 37: 463-496, 1968.
59. Rowe PS, de Zoysa PA, Dong R, Wang HR, White KE, Econs MJ, Oudet CL. MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia. Genomics 67: 54-68, 2000.
60. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34: 303-319, 2004.
61. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005.
62. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int 65: 1-14, 2004.
63. Segawa H, Kaneko I, Yamanaka S, Ito M, Kuwahata M, Inoue Y, Kato S, Miyamoto K. Intestinal Na-P(i) cotransporter adaptation to dietary P(i) content in vitamin D receptor null mice. Am J Physiol Renal Physiol 287: F39-F47, 2004.
64. Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol 23: 1203-1210, 2008.
65. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004.
66. Shimada T, Kakitani M, Hasegawa H, Yamzaki Y, Ohguma A, Takeuchi Y, ujita T, Fukumota S, Tomizuka K, Yamashita Y. Targeted ablation of FGF-23 causes hyperphosphatemia, increased 1,25-dihydroxyvitamin D Levels and severe growth retardation. J Bone Miner Res 17, Suppl 1: S168, 2002.
67. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98: 6500-6505, 2001.
68. Shimada T, Urakawa I, Yamazaki Y, Hasegawa H, Hino R, Yoneya T, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 314: 409-414, 2004.
69. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, HJAP, Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004.
70. Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am J Pathol 169: 2161-2170, 2006.
71. Sommer S, Berndt T, Craig T, Kumar R. The phosphatonins and the regulation of phosphate transport and vitamin D metabolism. J Steroid Biochem Mol Biol 103: 497-503, 2007.
72. Steele TH, Engle JE, Tanaka Y, Lorenc RS, Dudgeon KL, DeLuca HF. Phosphatemic action of 1,25-dihydroxyvitamin D3. Am J Physiol 229: 489-495, 1975.
73. Steele TH, Underwood JL. Renal response to phosphorus deprivation in the isolated rat kidney. Kidney Int 13: 124-128, 1978.
74. Stock AM, Robinson VL, Goudreau PN. Two-component signal transduction. Annu Rev Biochem 69: 183-215, 2000.
75. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18: 2116-2124, 2007.
76. Suzuki S, Ferjani A, Suzuki I, Murata N. The SphS-SphR two component system is the exclusive sensor for the induction of gene expression in response to phosphate limitation in synechocystis. J Biol Chem 279: 13234-13240, 2004.
77. Tanaka Y, Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 154: 566-574, 1973.
78. Tanaka Y, Deluca HF. Role of 1,25-dihydroxyvitamin D3 in maintaining serum phosphorus and curing rickets. Proc Natl Acad Sci USA 71: 1040-1044, 1974.
79. Tsujikawa H, Kurotaki Y, Fujimori T, Fukuda K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 17: 2393-2403, 2003.
80. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006.
81. Williams KB, DeLuca HF. Characterization of intestinal phosphate absorption using a novel in vivo method. Am J Physiol Endocrinol Metab 292: E1917-E1921, 2007.
82. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118: 722-734, 2008.